NYMX(Delisted)
Nymox Pharmaceutical·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NYMX
Nymox Pharmaceutical Corporation
A biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer
Bay & Deveaux Streets, Nassau, The Bahamas
--
Nymox Pharmaceutical Corporation was established in May 1995 after acquiring all the common stock of DMS Pharmaceutical Inc. Biopharmaceuticals under the Canadian Commercial Company Act. Since 1989, Nymox Pharmaceutical Corporation has been researching and developing diagnostic methods and drugs for Alzheimer's disease and brain diseases in the elderly. The company also holds US and global patents on statins for the treatment and prevention of Alzheimer's disease. They focused on the development of NX-1207 for the treatment of BPH and low-grade localized prostate cancer. The company currently sells NicAlertTM and TobacAlertTM, which detect the use of tobacco products by testing urine or saliva. The company has a patent portfolio covering its market products, its investigational drugs, and other therapeutic and diagnostic indications.
Company Financials
EPS
NYMX has released its 2023 Q1 earnings. EPS was reported at -0.02, versus the expected 0, missing expectations. The chart below visualizes how NYMX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
